Obesity & liver diseases

Product Name
Preclinical
Phase 1
Phase 2
Phase 3
Status1
Preclinical
Phase 1
Phase 2
Phase 3
Pemvidutide
(ALT-801)

Obesity

70%
Status1
End of Phase 2 FDA Meeting midyear 2024
Pemvidutide
(ALT-801)

NASH

55%
Status1
IMPACT Phase 2b NASH trial top line data in Q1 2025
Preclinical
Phase 1
Phase 2
Phase 3
HepTcell

Chronic HBV

55%
Status1
Top line data in Q1 2024